Thiazolidinediones Linked to Risk for Osteoporotic Fracture | medReha
3609
post-template-default,single,single-post,postid-3609,single-format-standard,bridge-core-3.0.2,qode-page-transition-enabled,ajax_fade,page_not_loaded,,qode-child-theme-ver-1.0.0,qode-theme-ver-28.8,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,wpb-js-composer js-comp-ver-6.9.0,vc_responsive

Thiazolidinediones Linked to Risk for Osteoporotic Fracture

Αρχική > Ιατρικά Άρθρα  > Παθήσεις  > Μυοσκελετικές  > Thiazolidinediones Linked to Risk for Osteoporotic Fracture

09 Μαρ Thiazolidinediones Linked to Risk for Osteoporotic Fracture

Posted at 11:59h in Μυοσκελετικές by
0 Likes

Thiazolidinediones (TZDs), which are used to treat type 2 diabetes mellitus, are associated with a 1.3-fold elevation in risk for osteoporotic fracture compared with other antidiabetic medications, according to a report published online March 6 in Pharmacoepidemiology and Drug Safety.

Read the full article from here:

http://www.medscape.com/viewarticle/759885?sssdmh=dm1.765109&src=nldne

 

  • This study was supported by a grant from the European Calcified Tissue Society and by the Dutch Organisation of Scientific Research. The Department of Pharmacoepidemiology and Clinical Pharmacology, which employs Dr. Bazelier and 3 coauthors, has received unrestricted funding for pharmacoepidemiologic research from GlaxoSmithKline, Novo Nordisk, the private–public-funded Top Institute Pharma, the Dutch Medicines Evaluation Board and the Dutch Ministry of Health. Two coauthors also work for the General Practice Research Database in the United Kingdom.
  • Pharmacoepidemiol Drug Saf. Published online March 6, 2012.

    Share
    Tags:
    ,